Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | RXRG | P48443 | 2/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655356 | 0.86 | PPARD (0.44) | PPARDPPARAKDM4EMEN1HSP90AA1 | |
| SCHEMBL137510 | 0.84 | HSP90AB1 (0.47) | KDM4EMAPTRXRARXRBRXRG | |
| SCHEMBL3651171 | 0.83 | RXRA (0.54) | PPARDPPARAKDM4EMEN1HSP90AA1 | |
| SCHEMBL11988716 | 0.83 | PPARD (0.43) | PPARDPPARAKDM4EMEN1HSP90AA1 | |
| SCHEMBL477855 | 0.82 | PSEN1 (0.60) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL491528 | 0.81 | RXRA (0.47) | PPARDPPARAKDM4EMEN1HSP90AA1 | |
| SCHEMBL1045007 | 0.80 | MAPT (0.56) | PPARAKDM4EMEN1HSP90AA1MAPT | |
| SCHEMBL3566072 | 0.80 | PPARD (0.50) | PPARDPPARAPPARGRXRARXRB | |
| SCHEMBL3566076 | 0.79 | PPARD (0.44) | PPARDPPARAMAPTPPARGRXRA | |
| SCHEMBL5444853 | 0.78 | PPARD (0.54) | PPARDPPARAPPARGRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016039-B1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO MCNEIL JANSSEN PHARM (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7825160-B2 | such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity | CELLZOME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| EP-1847524-B1 | Terphenyl derivatives for treatment of Alzheimer's disease | CELLZOME LTD (GB) | 2009-10-14 | — | — | EP | disclosed |
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | CELLZOME AG (DE) | 2009-05-07 | — | — | US | disclosed |
| EP-1805129-B1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| EP-2016039-A1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007124351-A1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1847524-A1 | Terphenyl derivatives for treatment of Alzheimer's disease | Cellzome (UK) Ltd. (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1805129-A1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME AG (DE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045554-A1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME AG (DE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | BACE1, BACE2, APP | PPARD 455/4885PPARA 327/4885KDM4E 1252/4885 |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | BACE1, BACE2, APP | PPARD 488/4885PPARA 790/4885KDM4E 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.